Overview

This trial is active, not recruiting.

Condition hepatic encephalopathy.
Treatment sildenafil.
Phase phase 1/phase 2
Sponsor Postgraduate Institute of Medical Education and Research
Start date July 2012
End date November 2013
Trial size 50 participants
Trial identifier NCT02028429, Hepatology PGIMER 2012

Summary

The study is being conducted to evaluate the efficacy of Sildenafil (a 5-phosphodiesterase inhibitor) as a means to improve the cognitive impairment encountered in patients of minimal hepatic encephalopathy (MHE) as proposed in different studies.

This study would also assess the role of improvement of cognition as a means of improvement in quality of life.The patients will receive Sildenafil or no treatment for 4 weeks.

This study may prove and provide important therapeutic strategy for cognition impairment in patients with MHE.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
MHE patient receiving Sildenafil. Intervention: Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
sildenafil. Suhagra.
Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
(No Intervention)
Control Arm: MHE patients not receiving SIldenafil Intervention.Followed up for 4 weeks.

Primary Outcomes

Measure
Cognition( PHES)
time frame: 4 weeks
QOL(SIP)
time frame: 4 weeks

Secondary Outcomes

Measure
CTP and MELD score before and after treatment with Sildenafil.
time frame: 4 weeks
Blood Ammonia and Interleukin-6 levels before and after treatment with Sildenafil.
time frame: 4 weeks

Eligibility Criteria

Male participants from 18 years up to 70 years old.

Inclusion Criteria: • Male patients aged 18-70 years diagnosed to have cirrhosis of liver at Liver Clinic of Department of Hepatology, PGIMER Chandigarh by means of clinical, biochemical and ultrasonographical/CT or liver biopsy. - MHE will be defined by PHES ≤-5 and normal MMSE score of ≥24. Exclusion Criteria: - Patients unable to give informed consent. - H/O alcohol intake during last 12 weeks. - Significant comorbid illness such as heart disease, respiratory disease, or renal failure. - Any neurological disease such as Alzheimer disease, Parkinson's disease, stroke, non- hepatic metabolic encephalopathy's. - Any anatomical deformities or disease of the penis such as Peyronie's disease. - Patients having psychiatric illness and taking treatment with antidepressant, sedative or neuroleptics. - Patients who start taking alcohol during the study period will be excluded. - Patients taking vasodilators such as nitrates. - Hepatocellular carcinoma. - Recent history of upper GI bleed in last 6 weeks. - Active ongoing infection. - Electrolyte abnormality precipitating MHE. - Color vision abnormalities.

Additional Information

Official title To Study The Proof of Concept in The Improvement of Cognition and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy by Means of a Pharmacological Intervention With Sildenafil (A Phosphodiesterase-5 Inhibitor).
Principal investigator Radha K Dhiman, MD, DM, FACG
Description Primary Aim 1. To study the proof of concept in the improvement of impairment in cognition as assessed by PHES (psychometric hepatic encephalopathy score) in patients of MHE by means of pharmacological intervention by Sildenafil (a phosphodiesterase(PDE)-5 inhibitor) before and after treatment. 2. To study the impact of treatment with Sildenafil administration on the improvement in health-related quality-of-life of patients as assessed by Sickness impact profile (SIP) before and after treatment. Secondary Aim 1. To study the impact of treatment with Sildenafil on CTP and MELD scores before and after treatment. 2. To study the impact of treatment with Sildenafil on blood ammonia and Interleukin-6 levels before and after treatment. Study Population: The study population comprises of male adult (age 18-70 years) with cirrhosis of liver. Patients with cirrhosis of liver have been divided into two groups - with MHE and without or no MHE (NMHE) based on the test result of PHES, i.e., abnormal (MHE group) or normal (NMHE group). Inclusion Criteria: - Male patients aged 18-70 years diagnosed to have cirrhosis of liver at Liver Clinic of Department of Hepatology, Postgraduate Institute of Medical Education & Research(PGIMER), Chandigarh by means of clinical, biochemical and ultrasonographical/CT or liver biopsy. - MHE will be defined by PHES ≤-5 and normal Mini-Mental State Examination (MMSE) score of ≥24. Exclusion Criteria: - Patients unable to give informed consent. - H/O alcohol intake during last 12 weeks. - Significant comorbid illness such as heart disease, respiratory disease, or renal failure. - Any neurological disease such as Alzheimer disease, Parkinson's disease, stroke, non- hepatic metabolic encephalopathy's. - Any anatomical deformities or disease of the penis such as Peyronie's disease. - Patients having psychiatric illness and taking treatment with antidepressant, sedative or neuroleptics. - Patients who start taking alcohol during the study period will be excluded. - Patients taking vasodilators such as nitrates. - Hepatocellular carcinoma. - Recent history of upper GI bleed in last 6 weeks. - Active ongoing infection. - Electrolyte abnormality precipitating MHE. - Color vision abnormalities.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by Postgraduate Institute of Medical Education and Research.